539 related articles for article (PubMed ID: 34781035)
1. Peptide-YY
Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
[TBL] [Abstract][Full Text] [Related]
2. Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice.
Boland BB; Mumphrey MB; Hao Z; Townsend RL; Gill B; Oldham S; Will S; Morrison CD; Yu S; Münzberg H; Rhodes CJ; Trevaskis JL; Berthoud HR
Mol Metab; 2019 Jul; 25():64-72. PubMed ID: 31126840
[TBL] [Abstract][Full Text] [Related]
3. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
4. Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice.
Carmody JS; Muñoz R; Yin H; Kaplan LM
Am J Physiol Endocrinol Metab; 2016 May; 310(10):E855-61. PubMed ID: 27026085
[TBL] [Abstract][Full Text] [Related]
5. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
6. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X receptor contributes to body weight-independent improvements in glycemic control after Roux-en-Y gastric bypass surgery in diet-induced obese mice.
Li K; Zou J; Li S; Guo J; Shi W; Wang B; Han X; Zhang H; Zhang P; Miao Z; Li Y
Mol Metab; 2020 Jul; 37():100980. PubMed ID: 32305491
[TBL] [Abstract][Full Text] [Related]
8. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
[TBL] [Abstract][Full Text] [Related]
10. Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission.
Pop LM; Mari A; Zhao TJ; Mitchell L; Burgess S; Li X; Adams-Huet B; Lingvay I
Diabetes Obes Metab; 2018 Jul; 20(7):1710-1721. PubMed ID: 29532631
[TBL] [Abstract][Full Text] [Related]
11. Reduction of Plasma BCAAs following Roux-en-Y Gastric Bypass Surgery Is Primarily Mediated by FGF21.
Shah H; Kramer A; Mullins CA; Mattern M; Gannaban RB; Townsend RL; Campagna SR; Morrison CD; Berthoud HR; Shin AC
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049555
[TBL] [Abstract][Full Text] [Related]
12. The role of peptide YY in appetite regulation and obesity.
Karra E; Chandarana K; Batterham RL
J Physiol; 2009 Jan; 587(1):19-25. PubMed ID: 19064614
[TBL] [Abstract][Full Text] [Related]
13. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones.
Nannipieri M; Baldi S; Mari A; Colligiani D; Guarino D; Camastra S; Barsotti E; Berta R; Moriconi D; Bellini R; Anselmino M; Ferrannini E
J Clin Endocrinol Metab; 2013 Nov; 98(11):4391-9. PubMed ID: 24057293
[TBL] [Abstract][Full Text] [Related]
14. Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.
Yang L; Yao D; Yang H; Wei Y; Peng Y; Ding Y; Shu L
Mol Endocrinol; 2016 Mar; 30(3):361-71. PubMed ID: 26789107
[TBL] [Abstract][Full Text] [Related]
15. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
[TBL] [Abstract][Full Text] [Related]
16. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
[TBL] [Abstract][Full Text] [Related]
17. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor.
Douros JD; Lewis AG; Smith EP; Niu J; Capozzi M; Wittmann A; Campbell J; Tong J; Wagner C; Mahbod P; Seeley R; D'Alessio DA
Diabetes; 2018 Aug; 67(8):1504-1511. PubMed ID: 29759973
[TBL] [Abstract][Full Text] [Related]
19. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
[TBL] [Abstract][Full Text] [Related]
20. Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist.
Grunddal KV; Diep TA; Petersen N; Tough IR; Skov LJ; Liu L; Buijink JA; Mende F; Jin C; Jepsen SL; Sørensen LME; Achiam MP; Strandby RB; Bach A; Hartmann B; Frimurer TM; Hjorth SA; Bouvier M; Cox H; Holst B
Mol Metab; 2021 Jul; 49():101207. PubMed ID: 33711555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
